BioStock: Stayble Therapeutics CEO comments on positive interim results
Stayble Therapeutics has presented interim results from the phase IIb study with STA363 demonstrating good safety and tolerability, thus giving the opportunity for a conclusive outcome. At the same time, the company has announced delays caused by the pandemic’s effects on patient recruitment. In Russia, where the majority of patients are to be recruited, infection rates and death rates are currently very high. Therefore, Stayble Therapeutics expects to present top line results during 2023. BioStock contacted the company’s CEO Andreas Gerward for a comment.
Read the interview with CEO Andreas Gerward at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se